Starpharma Holdings Limited (AU:SPL)
ASX:SPL
Want to see AU:SPL full AI Analyst Report?
SPL Stock Chart & Stats
AU$0.38
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.38
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.75
Previous CloseN/A
Volume337.59K
Average Volume (3M)724.95K
Market Cap
AU$307.28M
Enterprise ValueAU$285.61M
Total Cash (Recent Filing)AU$18.25M
Total Debt (Recent Filing)AU$790.00K
Price to Earnings (P/E)27.6
Beta1.27
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding420,928,440
10 Day Avg. Volume366,126
30 Day Avg. Volume724,950
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)1.93
Price to Sales (P/S)7.47
P/FCF Ratio-5.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Technology PlatformA proprietary dendrimer platform is a durable competitive asset: it supports multiple drug-delivery and anti-infective applications, creates licensing optionality, and sustains long-term R&D pipelines. This structural IP base can generate repeatable partnership and product opportunities over years.
Diversified Monetization StreamsHaving both licensing/collaboration income and in-house product sales reduces dependence on a single revenue source. Licensing provides milestone/royalty upside with low incremental capex, while product sales allow direct margin capture—together improving long-term revenue durability and strategic optionality.
Conservative Balance Sheet LeverageLow leverage gives the company enduring financial flexibility to fund multi-year biotech programs and absorb R&D volatility without immediate refinancing pressure. A stronger equity ratio supports longer development horizons and reduces insolvency risk during trial and commercialization cycles.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flows indicate ongoing cash burn and reliance on external funding. Over a 2–6 month horizon this weakens the company's ability to self-fund R&D or commercialization, increases dilution risk from capital raises, and constrains long-term strategic investment capacity.
Persistent UnprofitabilityContinued negative EBIT and net income show structural operating losses despite revenue gains. This highlights either cost structure or margin realization issues; without sustained margin improvement, profitability timelines remain uncertain and earnings power is limited over the medium term.
Negative Return On EquityA negative ROE signals that deployed capital is not producing shareholder returns, reflecting either unprofitable operations or inefficient capital allocation. Persistently negative ROE undermines long-term value creation and may pressure management to alter strategy or raise additional capital.
Starpharma Holdings Limited News
SPL FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest share price was AU$0.08 and its highest was AU$0.75 in the past 12 months.
What is Starpharma Holdings Limited’s market cap?
Starpharma Holdings Limited’s market cap is AU$307.28M.
When is Starpharma Holdings Limited’s upcoming earnings report date?
Starpharma Holdings Limited’s upcoming earnings report date is Aug 26, 2026 which is in 117 days.
How were Starpharma Holdings Limited’s earnings last quarter?
Starpharma Holdings Limited released its earnings results on Feb 17, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.
Is Starpharma Holdings Limited overvalued?
According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued.
Does Starpharma Holdings Limited pay dividends?
Starpharma Holdings Limited does not currently pay dividends.
What is Starpharma Holdings Limited’s EPS estimate?
Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Starpharma Holdings Limited have?
Starpharma Holdings Limited has 420,928,440 shares outstanding.
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Starpharma Holdings Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
Currently, no hedge funds are holding shares in AU:SPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Starpharma Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
355.55%
12-Months-Change
Fundamentals
Return on Equity
-15.96%
Trailing 12-Months
Asset Growth
-4.84%
Trailing 12-Months
Company Description
Starpharma Holdings Limited
Starpharma Holdings Limited (SPL) is an Australian biotechnology company focused on the development of innovative drug delivery systems and new therapeutic products. The company specializes in dendrimer technology, which allows for enhanced delivery of drugs and provides unique solutions in various sectors, including pharmaceuticals and personal care. SPL's core products include its proprietary VivaGel, a dendrimer-based gel for the treatment of bacterial vaginosis and prevention of sexually transmitted infections, as well as collaborations in the development of oncology drugs.
Technical Analysis
Immutep Ltd
―
Dimerix Limited
―
AnteoTech Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---